Chronic Cough - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chronic Cough - Pipeline Review, H2 2016

Chronic Cough - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chronic Cough - Pipeline Review, H2 2016
Published Sep 28, 2016
61 pages — Published Sep 28, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Chronic Cough - Pipeline Review, H2 2016, provides an overview of the Chronic Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Cough
- The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects
- The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Cough

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8503IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Chronic Cough Overview71
Therapeutics Development82
  Pipeline Products for Chronic Cough Overview81
  Pipeline Products for Chronic Cough Comparative Analysis91
Chronic Cough Therapeutics under Development by Companies101
Chronic Cough Therapeutics under Investigation by Universities/Institutes111
Chronic Cough Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Chronic Cough Products under Development by Companies141
Chronic Cough Products under Investigation by Universities/Institutes151
Chronic Cough Companies Involved in Therapeutics Development169
  Afferent Pharmaceuticals, Inc.161
  AstraZeneca Plc171
  Conrig Pharma ApS181
  GlaxoSmithKline Plc191
  Glenmark Pharmaceuticals Ltd.201
  GW Pharmaceuticals Plc211
  NeRRe Therapeutics Ltd221
  Patara Pharma, Inc.231
  Pila Pharma AB241
Chronic Cough Therapeutics Assessment258
  Assessment by Monotherapy Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type321
Drug Profiles3318
  AF-219 Drug Profile334
  cromolyn sodium Drug Profile371
  GRC-17536 Drug Profile382
  GSK-2339345 Drug Profile401
  lesogaberan Drug Profile411
  NEO-5937 Drug Profile421
  orvepitant maleate Drug Profile432
  S-1226 Drug Profile452
  Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases Drug Profile471
  ST-015 Drug Profile481
  XEND-0501 Drug Profile492
Chronic Cough Dormant Projects511
Chronic Cough Discontinued Products521
Chronic Cough Product Development Milestones537
  Featured News &Press Releases531
    Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis531
    May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference542
    May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors561
    Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial561
    Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet571
    Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company s Lead P2X3 Antagonist, AF-219582
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chronic Cough - Pipeline Review, H2 2016" Sep 28, 2016. Alacra Store. May 07, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Cough-Pipeline-Review-H2-2016-2088-16616>
  
APA:
Global Markets Direct - Market Research. (2016). Chronic Cough - Pipeline Review, H2 2016 Sep 28, 2016. New York, NY: Alacra Store. Retrieved May 07, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Cough-Pipeline-Review-H2-2016-2088-16616>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.